Vadastuximab disitamab vedotin antibody-drug conjugate representing a crucial advancement in the treatment of acute myeloid leukemia (AML). This pioneering therapy precisely targets CD33, a antigen frequently https://marvinyujy317591.wikicommunications.com/user